Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pan-Retinal Photocoagulation With Intravitreal Ranibizumab In Treatment Of Proliferative Diabetic Retinopathy
NCT07819253Completed
- Sponsor
- Aswan University
- Start
- Jul 2023
- Primary completion
- Jul 2025
- Countries
- 1
01
Overview
Trial of ranibizumab in proliferative diabetic retinopathy (PDR) (2 arms), sponsored by Aswan University. Primary endpoint: Macular vessel density changes at 3 months. Started Jul 2023; status: completed.
02
Drugs
ranibizumab
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on NCT07819253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07819253.